Correlation Between Oncopeptides and Cantargia

Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Cantargia at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Cantargia into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oncopeptides AB and Cantargia AB, you can compare the effects of market volatilities on Oncopeptides and Cantargia and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Cantargia. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Cantargia.

Diversification Opportunities for Oncopeptides and Cantargia

0.87

Correlation Coefficient

Oncopeptides  Cantargia

Very poor diversification

The 3 months correlation between Oncopeptides and Cantargia is 0.87. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Cantargia AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cantargia AB and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Cantargia. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cantargia AB has no effect on the direction of Oncopeptides i.e., Oncopeptides and Cantargia go up and down completely randomly.

Pair Corralation between Oncopeptides and Cantargia

Assuming the 90 days trading horizon Oncopeptides AB is expected to generate 0.67 times more return on investment than Cantargia. However, Oncopeptides AB is 1.48 times less risky than Cantargia. It trades about -0.07 of its potential returns per unit of risk. Cantargia AB is currently generating about -0.17 per unit of risk. If you would invest  216.00  in Oncopeptides AB on August 31, 2024 and sell it today you would lose (47.00) from holding Oncopeptides AB or give up 21.76% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Oncopeptides AB  vs.  Cantargia AB

Oncopeptides AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Cantargia AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cantargia AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Oncopeptides and Cantargia

The main advantage of trading using opposite Oncopeptides and Cantargia positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Cantargia can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cantargia will offset losses from the drop in Cantargia's long position.

The idea behind Oncopeptides AB and Cantargia AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.